(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 June 2008 (26.06.2008)

PCT

(10) International Publication Number
WO 2008/076247 A3

(51) International Patent Classification:
C07D 403/10 (2006.01) *A61P 9/12* (2006.01)
A61K 31/41 (2006.01)

(21) International Application Number:
PCT/US2007/025233

(22) International Filing Date:
11 December 2007 (11.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/874,630 13 December 2006 (13.12.2006) US

(71) Applicants *(for all designated States except US)*: **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0900 (US). **NICOX S.A.** [FR/FR]; Taissounières HB4, 1681 Route Dolines-BP313, F-06560 Sophia Antipolis, Valbonne (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SEBHAT, Iyassu, K.** [GB/US]; Merck & Co., Inc., 126 East Lincoln Avenue, P.O.box 2000, Rahway, NJ 07065-0900 (US). **LO, Michael, Man-Chu** [CN/US]; Merck & Co., Inc., 126 East Linclon Avenue, P.O.box 2000, Rahway, NJ 07065-0900 (US). **NARUGUND, Ravi, P.** [US/US]; Merck & Co., Inc., 126 East Licoln Avenue, P.O.box 2000, Rahway, NJ 07065-0900 (US). **ALI, Amjad** [GB/US]; Merck & Co., Inc., 126 East Lincoln Avenue, P.O.box 2000, Rahway, NJ 07065-0900 (US). **FRANKLIN, Chris** [US/US]; Merck & Co., Inc., 126 East Lincloln Avenue, P.O.box 2000, Rahway, NJ 07065-0900 (US). **ALMIRANTE, Nicoletta** [IT/IT]; Via Caracciolo, I-26-20155 Milano (IT). **STORONI, Laura** [IT/IT]; Via Dante, I-57-20031 Casano Mademo(Milano) (IT). **STEFANINI, Silvia** [IT/IT]; Via Marandi, I-11/B - 20097 San Donato Milanese(MI) (IT).

(74) Agent: **PAREZO, Jessica, L.**; Covington & Burling LLP, 1201 Pennsylvania Avenue N.W., Washington, DC 20004-2401 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
15 January 2009

(54) Title: NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS



(I)

(57) Abstract: A compound having the structure (Formula I), wherein R is an angiotensin receptor antagonist active group, Y is $-Y^1-Y^2-Y^3-Y^4-Y^5-$; Y^1 is $C(R^1R^2)$; R^1 is selected from the group consisting of hydrogen and C_{1-4} alkyl; R^2 is selected from the group consisting of hydrogen, C_{1-4} alkyl, and $-OC(O)C_{1-4}$ alkyl; Y^2 is O or CH_2; Y^3 is C(O) or CH_2; Y^4 is O or CH_2; Y^5 is $-(CH2)_{1-2}-(X)_{0-1}-(CH_2)_{0-1}-$ or is absent; X is -O- or $-CR^3R^4-$; and R^3 and R^4 are independently selected from the group consisting of hydrogen and C_1-C_4 alkyl; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.

WO 2008/076247 A3